Banco Santander S.A. Invests $7.31 Million in Biogen Inc. (NASDAQ:BIIB)

Banco Santander S.A. purchased a new stake in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 47,809 shares of the biotechnology company’s stock, valued at approximately $7,311,000.

Several other large investors have also recently added to or reduced their stakes in BIIB. Ashton Thomas Securities LLC bought a new stake in shares of Biogen in the third quarter valued at about $33,000. SRS Capital Advisors Inc. bought a new stake in Biogen in the 4th quarter valued at about $33,000. Golden State Wealth Management LLC acquired a new position in shares of Biogen during the 4th quarter worth approximately $41,000. Venturi Wealth Management LLC increased its holdings in shares of Biogen by 73.8% during the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 93 shares during the period. Finally, Itau Unibanco Holding S.A. raised its position in shares of Biogen by 63.8% in the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 90 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BIIB shares. Needham & Company LLC reissued a “hold” rating on shares of Biogen in a research report on Thursday, February 13th. William Blair reissued an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Wolfe Research started coverage on Biogen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. BMO Capital Markets reduced their price objective on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a research note on Thursday, February 13th. Finally, Royal Bank of Canada decreased their target price on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $213.33.

Biogen Stock Up 2.0 %

Shares of BIIB opened at $150.38 on Friday. The stock’s 50-day moving average price is $143.98 and its two-hundred day moving average price is $166.46. Biogen Inc. has a 12 month low of $128.51 and a 12 month high of $238.00. The company has a market capitalization of $22.01 billion, a PE ratio of 13.44, a PEG ratio of 1.51 and a beta of 0.01. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.